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RECONSIDERING FIRST-LINE ANTIRETROVIRAL THERAPY 
IN THE PREGNANT POPULATION 
SUNNY YOO 
ABSTRACT 
Too many children are still being newly infected with HIV. The Global Plan is to 
eliminate new HIV infections among children by 2015 and keep their mothers alive. The 
rate of MTCT of HIV-1 has fallen to less than 2% in countries with the implementation 
of recommendations. The best documented factor that correlates to higher rates of 
transmission is the maternal level of plasma viremia. Therefore it is important to 
maximally inhibit HIV replication in order to prevent HIV-associated morbidity and 
mortality and to prevent MTCT. Durable viral suppression prolongs life by improving 
immune function and overall quality of life, lowering the risk of both AIDs-defining and 
non-AIDS-defining complications. 
Clinical data are more limited on antiretroviral drugs in pregnant women than in 
non-pregnant individuals due to concerns for maternal and fetal safety, ethical 
considerations, the difficulty in designing appropriate trials to assess the study objectives, 
and funding limitations. However there are sufficient data to base recommendations for 
drug choice for many of the available antiretroviral drugs. Preferred drugs must show 
durable viral suppression, increased CD4 cell count, and a favorable safety profile. In 
addition to the aforementioned characteristics of a preferred drug, preferred antiretroviral 
drugs for pregnant individuals must pay special attention to maternal toxicity, potential 
teratogenicity, and fetal safety, efficacy of reducing perinatal transmission, and 
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pharmacokinetics data during the perinatal transmission of HIV. 
Currently the optimal initial antiretroviral regimens to treat antiretroviral-naïve 
patients in high resource regions consist of two nucleoside/tide reverse transcription 
inhibitors in combination with either a nonnucleoside reverse transcriptase inhibitor or a 
protease inhibitor boosted with RTV. Continually re-evaluation is recommended to 
challenge current paradigms. Treatment advances may lead to safer and even superior 
alternatives to current first-line therapy. 
The WHO current first-line therapy in less developed or developing regions 
includes the nonnucleoside reverse transcriptase inhibitor, EFV and considerations of 
poorer overall efficacy compared to newer drugs, toxicity, resistance, and adverse effects 
suggest that EFV should be reconsidered for use in first-line therapy. Although preferred 
protease inhibitors are as effective as EFV with fewer adverse effects, serious issues arise 
when patients are on concomitant medications with drug interactions. 
Currently raltegravir is the only integrase strand transfer inhibitor drug (INSTI) 
with data during pregnancy. Raltegravir is an attractive alternative or additional drug for 
pregnant women requiring medications with resistance, incomplete virologic response, or 
significant interactions with current first-line regimen drugs. Furthermore, based on 
recent data, raltegravir could provide pre-exposure prophylaxis in the fetus. DTG is a 
newer generation INSTI with clinical trials data showing safety and efficacy in 
nonpregnant adults. These studies suggest great promise for DTG and justify its role as 
first-line therapy for the nonpregnant population with relatively few drug interactions; in 
addition, it offers the only single tablet regimen for patient with or at risk for renal 
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dysfunction. 
Although more data must be collected to ensure the safety and efficacy of INSTI 
as a first-line therapy in pregnant women, current studies show promise and with 
increasing experience INSTI agents may become part of the recommended first-line 
regimen for pregnant women. 
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INTRODUCTION 
 
HIV/AIDS – Definition/Classification 
Human immunodeficiency virus (HIV) is a human retrovirus, and infected 
adolescents and adults are categorized on the clinical conditions associated with HIV 
infection and Cluster of Differentiation 4 (CD4+) T lymphocyte counts. Profound 
immunodeficiency is the hallmark of HIV disease, resulting primarily from a quantitative 
and qualitative deficiency of helper T cells. Centers for Disease Control and Prevention 
(CDC) classifies HIV into three clinical categories and three ranges of CD4+ T 
lymphocyte counts which classify a person into one of the nine exclusive categories 
(Table 1). Regardless of the presence of symptoms or opportunistic diseases, a CD4+ T 
cell count of <200/µL is classified as acquired immunodeficiency syndrome (AIDS) by 
definition which includes categories A3, B3, C3. In addition categories C1 and C2 are 
considered to have AIDS. Once an individual is classified into category B or C, their 
disease classification cannot relapse back to category A or B, respectively, even if the 
clinical condition improves. The course of HIV disease from primary infection through 
the development of advanced-stage disease is complex and varied, the pathogenic 
mechanisms are multifactorial and multiphasic and are different at different stages of the 
disease. Documented HIV infection in an adolescent or adult with either one or more of 
the following conditions: asymptomatic, acute HIV, or progressive generalized 
lymphadenopathy (PGL) is classified as Category A. Category B consists of symptomatic 
conditions occurring in an HIV-infected adolescent or adult and meet either one or more 
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of the following conditions: indicate a defect in cell-mediated immunity or show to have 
a clinical course or management that is complicated by HIV infection. Category C is 
AIDS-indicator stage that has its conditions listed in the AIDS surveillance case 
definition. Some features of AIDS, such as certain neurologic abnormalities may occur 
prior to the development of severe immunologic impairment and therefore cannot be 
explained completely by the immunodeficiency caused by HIV infection. The definition 
of AIDS is complex and is designed for surveillance purposes instead of the practical care 
of a patient; therefore it is better viewed as a spectrum ranging from primary infection, to 
asymptotic syndrome, to advanced stages.1 
Table 1 Revised Classification System for HIV Infection and Expanded AIDS 
Surveillance Case Definition for Adolescents and Adults. The nine categories classify 
a person into one of the nine exclusive categories which are made of three clinical 
categories and three ranges of CD4+ T lymphocyte counts. 
 
 
Abbreviation: PGL, progressive generalized lymphadenopathy. 
Source: MMWR 42 (No. RR-17), December 18, 1992. 
 
Replication Cycle 
 HIV is a ribonucleic acid (RNA) virus that uses reverse transcriptase to undergo 
reverse transcription to generate a complementary deoxyribonucleic acid (cDNA) from 
an RNA template (Figure 1). The replication cycle starts when the envelope glycoprotein 
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GP120 (gp120) attaches to a receptor on the host cell, the CD4 molecule. Once bound, 
the gp120 undergoes conformational change which assists the binding to one of the two 
major co-receptors. The two major co-receptors for HIV-1 is C-C chemokine receptor 
type 5(CCR5) and C-X-C chemokine receptor type 4 (CXCR4).  The use of one, both, or 
either receptors by the virus for entry into the cell determines the cellular tropism of the 
virus. After the aforementioned conformational change, fusion occurs via the newly 
exposed glycoprotein 41 (g41) molecule entering the host cell, which allows the virion 
and host cell to come together, allowing the preintergration complex, composed of viral 
proteins and viral RNA enclosed in a capsid protein coat, to travel from the cytoplasm of 
the host cell to the nucleus. En route to the nucleus, reverse transcriptase catalyzes the 
RNA into DNA and the protein coat opens to release the double stranded proviral HIV-
DNA. Through the nuclear pore, the viral DNA can now access the nucleus and be 
integrated into the host cell chromosome by another viral enzyme, integrase. The provirus 
may have varying levels of gene expression or even remain latent.1  Some level of 
cellular activation is required in order to transcribe the provirus; this is dependent on a 
number of cellular transcription factors and the viral transactivator Tat.2 HIV messenger 
RNA (mRNA) is translated into proteins, after transcription. The protein will undergo 
modifications through glycosylation, myristoylation, phosphorylation, and cleavage. 
Through specialized regions of the cell plasma membrane, lipid rafts, budding of the 
progeny virion occurs. Protease, another viral enzyme, catalyzes the cleavage of the gag-
pol precursor to yield the mature virion. The virus reproductive cycle is dependent on 
multiple viral regulatory gene products, therefore there are a variety targets at the 
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reproductive cycle for therapeutic intervention.1 
 
 
Figure 1: The Replication Cycle for HIV. HIV is a RNA virus which uses reverse 
transcriptase to undergo reverse transcription to generate a cDNA from an RNA template 
Source: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscaizo J: 
Harrison’s Principles of Internal Medicine, 18th Edition: www.accessmedicine.com 
Copyright © The McGraw-Hill Companies, Inc. All rights reserved. 
 
Antiretroviral Drugs  
Most HIV-infected individuals will develop progressive immunosuppression, 
which will lead to AIDS-defining illness and premature death, without treatment. To 
prevent HIV-associated morbidity and mortality antiretroviral drugs (ARV) are used to 
maximally reduce HIV replication so that plasma HIV RNA or viral load, remains 
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beneath detectable by accessible assays. Long-lasting viral suppression prolongs life by 
recovering immune function and general quality of life, lowering the risk of both non-
AIDS-defining and AIDS-defining complications. Furthermore, a secondary goal of 
antiretroviral therapy (ART) is to lower occurrence and frequency of HIV in a 
population. Elevated plasma HIV RNA is a main risk factor for HIV transmission, thus 
effective ART can reduce viremia and the risk of HIV transmission. The most dramatic 
and well-established example of this is the use of ART in pregnant women to prevent 
perinatal transmission of HIV.3 
Currently the ARV approved drugs for adults and adolescent target viral enzymes 
or entry in order to halt the viral life cycle (Table 2). They fall into five categories: those 
that inhibit reverse transcriptase (nucleoside/tide reverse transcription inhibitors or NRTI; 
nonnucleoside reverse transcriptase inhibitors or NNRTI), those that inhibit protease 
enzyme (protease inhibitors or PI), those that interfere with entry (entry/fusion 
Inhibitors), those that inhibit integrase enzyme (integrase strand transfer inhibitors or 
INSTI), and boosters. Combination antiretroviral therapy (cART) is the foundation to 
manage patients with HIV infection. The most advantageous initial ARV course of 
therapy to treat ARV-naïve patient consists of two NRTIs in combination with a drug 
from one of these drug classes: an NNRTI, a PI boosted with ritonavir (RTV), or an 
INSTI.3 
Pharmacokinetic boosting is used to increase the plasma concentrations of 
coadministeredARV agents by inhibiting cytochrome P450 3A4 (CYP3A4). RTV and 
cobicistat are potent inhibitors of CYP3A4. Although RTV was initially developed as a 
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PI, it is currently used primarily as a pharmacokinetic boosting agent for other PIs. 
Therefore, RTV is able to enhance the effectiveness of PI treatment by improving the 
pharmacokinetic profiles of concomitant PIs, and it represents a cornerstone of PI-
containing regimens. Cobicistat is a new boosting agent approved for use with the INSTI 
elvitegravir (EVG) and the PIs atazanavir (ATV) and darunavir (DRV). Drugs 
contraindicated with RTV-containing PI regimens are also contraindicated with cobicistat 
in respect to CYP3A4 interactions. The boosted PI regimens require more pills have 
many medication-medication interactions and may have additional undesirable metabolic 
impacts, such as gastrointestinal problems and lipid disturbances. In patients with 
increased risk of metabolic abnormalities or comorbidities, the unboosted integrase-based 
regimens should be considered preferred choices.4 
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Table 2: FDA-Approved HIV Medicines. The approved FDA HIV medicines with their 
generic and brand names, divided into their drug classes.  
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Mother-to-Child-Transmission 
 HIV is the leading cause of death in women of reproductive age, globally. HIV 
can be transmitted by sexual contact, blood and blood products, by infected mothers to 
their infants, antepartum, intrapartum, or via breast milk. Mother-to-Child-Transmission 
(MTCT) during labor and delivery, (perinatal transmission) is the most common cause of 
Pediatric HIV infection.5 In 2013 an estimated 240,000 children were newly infected with 
HIV, 89% were in the WHO (World Health Organization) Africa region, 8% were in the 
WHO South-East Asia Region, 1% in the WHO Eastern Mediterranean Region and in the 
WHO Region of the Americas, and less than 1% in the WHO European and Western 
Pacific Regions. Too many children are still being newly infected with HIV. Wider use of 
more efficacious regimens have led to a substantial decline in overall MTCT rates and the 
annual number of children newly infected with HIV in low- and middle-income 
countries. In low- and middle-income countries, the estimated overall rate of MTCT of 
HIV declined to about 17% in 2013 from 26% in 2009. The global community has called 
for the elimination of new HIV infections among children by 2015 and keeping their 
mothers alive.6 
Without prophylactic ART to the mother and fetus, MTCT ranges from 15-25% 
in industrialized countries and from 25-35% in developing countries.1 Of HIV-infected 
mothers who are untreated and not breast-feeding, 15-40% of their offspring are 
infected.5 Transmission rates for breast feeding may be as high as 30-40% and are 
associated with systemic HIV viral burden.7-8 Studies have estimated a temporal 
distribution of vertical transmission: 20% of transmission occurs before 36 weeks of 
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gestation, 50% in the days before delivery, and 30% intrapartum.9-10 
Features like stage of disease, adequate prenatal care, mother’s health during 
pregnancy relate to the different rates of transmission.1 The best documented factor that 
correlates to higher rates of transmission is maternal level of plasma viremia.9  Cohort 
neonatal infection was > 30% when maternal viral RNA levels were >100,000 copies/mL 
and only 1% with < 400 copies/mL at delivery.10 However, MTCT has been observed at 
all HIV RNA levels, including those that were not detectable by current assays; this may 
be attributed to differences between the viral load in genital secretions and that of 
plasma.4 
Viral factors, host factors, and obstetric factors influence MTCT of HIV. 
Important viral factors include viral load in plasma, genitourinary tract, and breast milk. 
Viral characteristics such as genotype, phenotype, tropism, resistance to ARV agents, and 
capacity for immune escape influence MTCT of HIV. Important host factors include 
immunologic, genetic, and tissue/mucosal integrity. Immunologic factors such as 
maternal CD4 count-stage of HIV disease, maternal immune factors (neutralizing 
antibodies), fetal/neonatal immune response, and breast milk immune factors. Genetic 
factors include fetal human leukocyte antigen (HLA) type, maternal-fetal HLA 
concordance, single nucleotide polymorphisms (SNPs) for chemokines/chemokine 
receptors/innate immune factors. Chorioamnionitis/placental pathology /maturational 
stage, maternal genitourinary lesions/ sexually transmitted diseases, cracked or bleeding 
nipples/ breast abscess/ clinical or clinical mastitis, barrier integrity, infant 
gastrointestinal maturity, and vitamin A or other micronutrient deficiency are all host 
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factors that influence MTCT of HIV. Obstetric factors such as mode of delivery, timing 
of delivery, invasive monitoring/obstetric procedures, and duration of membrane rupture 
play an important role influencing MTCT of HIV.11 
 The rate of MTCT has fallen to 1% in pregnant women in the United States and 
Europe with the execution of suggestions for total prenatal HIV counseling and testing, 
ARV prophylaxis, obstetric management that focuses on minimizing exposure of the 
infant to maternal blood and genital secretions, scheduled cesarean delivery if maternal 
viral load exceeds 1000 copies/mL, and avoidance of breastfeeding.12-14 Due to lower 
cost of drugs, cART is becoming increasingly available to individuals in developing 
countries, benefitting the women, and blocking HIV transmission.1 
 
Antiretroviral Drug Resistance 
 When selecting for a more effective and durable ARV regimens, it is important to 
identify the baseline resistance mutations, comprehensive history of ARV drug use, and 
genotypic resistance testing. A main factor that develops in HIV-infected individuals is 
therapeutic failure, which is caused by ARV drug resistance. The development of 
resistance to drugs used during pregnancy to prevent MTCT may decrease the 
effectiveness of prophylactic regimens in the current pregnancy or limit future treatment 
options. If maternal drug resistance develops or is present, infant treatment options also 
may be limited if resistant virus is transmitted to the fetus. Under suboptimal drug 
pressure, HIV has an extraordinary intrapatient evolution rate that facilitates generation 
of drug-resistant variants.15 
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Resistance testing should be done on those who have not been previously tested 
for ARV resistance and before initiating cART treatment with patients that have HIV 
RNA levels above the threshold for resistance testing, >500 to 1,000 copies/mL. Testing 
in HIV-infected pregnant women should be done before initiating cART for those who 
have received ARVs to prevent MTCT in prior pregnancies and who plan to restart ARV 
drugs to prevent MTCT and only if HIV RNA levels are above the threshold for 
resistance testing. Testing is recommended before changing ARV regimen in HIV-
infected pregnant women with measurable HIV RNA levels that are exceed the threshold 
for resistance testing in HIV-infected pregnant women while on cART or to those who 
after starting cART during pregnancy still have suboptimal viral suppression. Typically, 
the results of resistance testing will direct selection of the initial ARV regimen. However, 
to optimize prevention of MTCT, clinicians may initiate an empiric ARV drug regimen 
before results are available, especially when a woman is in the third trimester. Most 
experts believe the possible risks do not outweigh the benefits of temporary use of a 
regimen that could be suboptimal because of preexisting resistance. Once resistance test 
results are obtained, the ARV drug course of therapy can be modified according to the 
results.15 
 There are several factors distinctive to pregnancy that may augment the risk of 
developing resistance. In early pregnancy where nausea and vomiting are common, 
adherence and/or bioavailability may be compromised and the risk of resistance in 
women receiving ARV drugs may increase. Pharmacokinetic changes due to pregnancy 
may lead to suboptimal drug concentrations, which may raise the threat that resistance 
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will develop. When ARV drugs with low genetic barriers to resistance and significant 
differences in half-life, such as an NNRTI combined with two NRTI, are discontinued 
simultaneously postpartum then it may result in an increased risk of NNRTI resistance 
because of persistent sub-therapeutic drug levels.15 
 Using and adhering to an effective cART regimen achieves maximal viral 
suppression and is the most effective way to prevent development of ARV drug 
resistance. Due to an increase in potential risk of perinatal HIV infection associated with 
detectable HIV viremia during pregnancy, more frequent monitoring of viral load in 
pregnant women is recommended.15 
 
Treatment for Pregnant Women in High-, Middle-, and Low-Income Countries 
 For high resource countries like the United States, treatment is recommended for 
all HIV-infected pregnant women because it reduces perinatal transmission regardless of 
CD4+ T cell count or HIV RNA level. ARV drugs should only be withheld when there 
are recognized unfavorable effects to the mother and fetus overall health that outweigh 
the benefits. The regimen should be individualized and it is important that the health care 
provider discusses the possible benefits and risks to the mother and her fetus because it is 
ultimately her judgment to use any ARV drug during pregnancy.15 
 For more resource limited countries, the 2013 WHO guidelines for the use of 
ARV drugs in pregnant and breastfeeding women represent a major paradigm shift from 
previous recommendations for prevention of MTCT. For the first time, the prevention of 
MTCT will no longer be determined by women’s health status. All women should initiate 
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standard first-line ART to reduce the risk of MTCT of HIV and to her uninfected 
partners, irrespective of CD4+ T-cell count or clinical stage. The ART strategy for 
pregnant women is fully harmonized with the recommended first-line regimen for 
nonpregnant adults, once-daily tenofovir (TDF) + lamivudine (3TC)/efavirenz (EFV) + 
emtracitabine.6 
 Pregnant and breastfeeding women with HIV may initiate ART as lifelong 
treatment, the option B+ approach, whereas in some resource limited countries, for 
women not eligible for ART for their own health, consideration can be given to stopping 
the ARV drug regimen after the period of MTCT risk has ceased, option B (Table 3).6 
Table 3: Summary of Recommendations for Use of Antiretroviral Drugs for 
Pregnant and Breastfeeding Women in 2013 WHO Guidelines. All women should 
initiate standard first-line ART to reduce MTCT of HIV, regardless of women’s health 
status. 
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US Guidelines 
The Panel of ARV Guidelines for Adults and Adolescents3, a committee under the 
auspices of the US Department of Health and Human Services, makes recommendations 
for the care of US HIV infected adults and adolescents based on data prepared by 
manufacturers for Food and Drug Administration (FDA) review and clinical trial data 
published in peer-reviewed journals. The first principle for selection of data on which to 
base these recommendations is available information from a randomized, prospective 
clinical trial with an adequate sample size that demonstrates that an ARV regimen has 
shown sustainable viral control, improved CD4 cell count, and has a positive safety 
report. Assessment of regimen efficacy and safety are based on rates of HIV RNA 
suppression, and the incidence and severity of adverse events because relative clinical 
trials of preliminary treatments generally show no noteworthy differences in HIV-related 
clinical endpoints. Similarly, the Panel on ARV Treatment of HIV-Infected Pregnant 
Women and Prevention of Perinatal Transmission15 (the Panel) makes recommendations 
for HIV infected pregnant women in the US similar to the way the Panel of ARV 
Guidelines for Adults and Adolescent bases their recommendations but they also pay 
particular focus on maternal toxicity and possible teratogenicity and fetal health; 
recognized effectiveness of ARV drug combinations in dropping MTCT of HIV; 
pharmacokinetic information throughout the prenatal period; and results from animal 
teratogenicity studies.15 
Factors to consider when selecting an initial regimen for naïve patients include 
outcome of HIV genotypic drug resistance testing, pretreatment HIV RNA level, the 
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regimen’s genetic barrier to resistance, potential adverse drug effects, known or potential 
drug interactions with other medications, the patient’s comorbid condition, pregnancy or 
pregnancy potential, HLA-B*5701 testing if considering Abacavir (ABC), patient 
preference and adherence potential, and convenience.3  On average, women during 
pregnancy take 2.6 drugs, including both prescription and nonprescription agents.16 
Additional factors to consider when selecting a regimen for pregnant patients are 
experience with use in pregnancy, potential adverse maternal drug effects that may begin 
new medical problems exacerbate old ones during pregnancy, pharmacokinetic 
alterations during pregnancy and extent of placental transport, possible teratogenic effects 
and other short/long-term undesirable effects on fetuses or newborns which include but 
not limited by premature births, muta- and carcino-genicity .15 
Although clinical data are more abundant on ARV drugs in non-pregnant women 
than in pregnant individuals, adequate information subsist on which to support approvals 
related to treatment preference for numerous of the existing ARV drugs. Drugs and drug 
regimens for pregnant ARV-naïve women are classified as preferred, alternative, 
insufficient data to recommend use, and not recommended. When clinical trial data in 
adults have demonstrated optimal effectiveness and stability with adequate and simplicity 
of use; pregnancy-specific pharmacokinetic data are available to direct dosing; and no 
reputable connection with teratogenic effects or clinically significant unfavorable results 
for mothers, fetuses, or newborns have been documented, then these drugs are elected as 
preferred for used in ARV-naïve pregnant women. When clinical trial data in adults 
demonstrate effectiveness but in the least one or more of the following circumstances 
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pertain; experience in pregnancy is partial; data are wanting on teratogenic effects on the 
fetus; or the drug or regimen is associated with dosing, formulation, administration, or 
interaction concerns, then these drugs are selected as alternative for initial therapy in 
ARV-naïve pregnant women. The drugs and drug combinations in the insufficient data to 
recommend class are accepted for use in adults but need pregnancy-specific 
pharmacokinetic or safety information or such data are too inadequate to make a 
recommendation for use in ARV-naïve pregnant women. Drugs in the final category, not 
recommended, are shown to have an inferior virologic response, potentially serious 
maternal or fetal safety concerns, or pharmacologic antagonism or are not recommended 
for ARV-naïve populations regardless of pregnancy status. For ARV-naïve women, a 
cART regimen including two NRTIs backbone and either a boosted PI or an NNRTI is 
preferable (Table 4).15 
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Table 4: Preferred Regimens for HIV-Infected Pregnant Women.  The drugs are 
classified into the preferred cART regimen for HIV-pregnant women and comments are 
listed alongside them. 
 
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women 
for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the 
United States 
Downloaded from http://aidsinfo.nih.gov/guidelines on 2/2/2015 
 
Recommended Treatment in HIV-Pregnant Women: NRTI Backbone 
Although ZDV/3TC is not recommended for preliminary treatment of HIV 
infection in nonpregnant adults it still remains a favored dual NRTI mixture for ARV-
naïve pregnant women, based on effectiveness studies to stop MTCT and wide practice 
with safe employ in pregnancy. However this NRTI combination requires twice-daily 
administration and has greater toxicities than other approved NRTI combination like 
TDF/emtricitabine (FTC) or ABC/3TC. The NRTI combinations of TDF/FTC or 
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ABC/3TC are also recommended regimens, and both are accessible as once daily fixed-
dose combination tablets. Another concern when choosing between NRTI combinations 
is potential adverse effects. TDF has possible renal and bone toxicity; therefore TDF-
based combinations ought to be used with carefulness in individuals with renal 
deficiency. The last concern when deciding on an NRTI combination is hepatitis B 
coinfection. In patients who also have chronic hepatitis B, TDF/FTC is the favored NRTI 
mixture because both agents have activity against HBV. In addition ABC in combination 
with 3TC is well tolerated and offers the advantage of once-daily dosing. However, in 
patients who test positive for HLA-B*5701, ABC should not be used due to potential 
hypersensitivity reactions which predicts hypersensitivity to this drug.17 Approximately 
eight percent of whites and two and a half percent of African Americans are positive for 
this allele.18 
 
Choosing the Third Drug in a cART Regimen 
 When choosing the third drug (NNRTI, PI, or INSTI) in a regimen, factors such 
as efficacy, adverse effects, convenience, genetic barrier to resistance, comorbidities, 
concomitant medications, and potential for drug-drug interactions are considered. 
Another important consideration is the adverse effects that are specific to particular drugs 
within each drug category. All the recommended NNRTI-, PI- and INSTI- based 
regimens are effective. In terms of ease, once-daily single-pill combinations are often 
preferred by both patients and clinicians because of their low pill burden and favorable 
dosing frequency. Regimens that include PIs have a greater pill burden, typically 3 pills 
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once a day. Boosted PI regimens include potent inhibitors of the CYP450 3A4 pathway; 
therefore there is a larger probability for drug-to-drug interactions than different 
mixtures. In individuals who are getting additional medication that are mainly 
metabolized through this pathway, regimens containing PIs may be a disadvantage. 
However, for patients with suboptimal or unidentified adherence and an elevated risk for 
virologic failure, some clinicians consider regimens that include PIs preferable because 
they generally require multiple viral mutations to reduce the agents in this category and 
virologic failure infrequently go for PI-resistance. If a regimen is started before the 
results of a HIV resistance testing are available, drugs in the PI class are favored because 
of the relatively uncommon drug resistance to PIs.3 
 
Non-Nucleoside Reverse Transcriptase Inhibitors 
The availability of EFV in a fixed-dose combination makes it an attractive 
treatment option, since it can be included into a once-daily, one-pill schedule with 
TDF/FTC.  For over 15 years it has been recommended as a preferred agent for first-line 
therapy in patients based on its virological and pharmacological characteristics, 
simplicity of dosing, high in vitro potency, amnesty in regard to mixed doses, and 
information from various randomized clinical studies established virological 
suppression.19  EFV is also the preferred regimen on the WHO guidelines in the 
nonpregnant and pregnant population.6 This is a first-line regimen in patients needing 
coadministration of drugs with noteworthy interactions with PIs.15 Compared to 
nevirapine- (NVP),20 rilpivirine (RPV)-21, 22 and ATV-based regimens23, EFV has been 
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shown to have similar anti-HIV activity in randomized comparative studies, course of 
therapies containing EFV were better virologically to several PI-based regimens, 
including indinavir-24, lopinavir-25, and nelfinavir-based regimens26, and to triple NRTI-
based regimens.27 
Despite its long use, EFV has its limitation and is being reconsidered as a first-
line ART because of its adverse events especially central nervous system (CNS) and 
psychiatric side effects, higher incidence of rash than with other recommended regimens, 
its inferior in general effectiveness compared with newer ARVs, its ranking as FDA 
Pregnancy Category D drug, dyslipidemia, and the relatively high occurrence of 
transmitted drug-resistance mutations.19 Due to potential teratogenicity, course of 
therapies that do not contain EFV ought to considered in females who wish to conceive 
or are sexually active. EFV is metabolized in the liver by CYP 3A isoenzymes and is also 
a substrate of CYP2B6 enzymes. In patients who are receiving other medications, 
treatments that contain EFV have possible drug-drug interactions because EFV acts as a 
mixed inducer and inhibitor of the CYP450 pathway, primarily inducing CYP3A and 
2B6 enzymes. Concomitantly administered drugs that inhibit or induce these enzymes 
can alter EFV concentrations, resulting in adverse effects or virologic failure. Table 5 list 
drugs that are contraindicated with EFV use. EFV is the preferred therapy in females 
requiring coadministration of drugs with noteworthy interactions with PI.15 
	    
	  22 
Table 5: Drugs that are Contradicted with the Use of ARV Drugs. Listed are some of 
the common drug categories and the drugs that are contraindicated with the use of ARV 
agents. 
 
 
 
EFV repeatedly causes CNS side effects: dizziness, abnormal dreams, headaches, 
and depression. These unfavorable effects are often resolved impulsively. However, some 
of these adverse can direct to regimen discontinuation. People who have tolerated EFV 
have reported improvements in mood when changing to other drugs.28 Meta-analysis of 
four randomized clinical studies in ART-naïve patients, suggest that the adjusted risk of 
suicidality was considerably higher in EFV than non-EFV receivers, with a ratio of 
2.28.29 Also a randomized study comparing cognitive change commencing different ARV 
regimen, showed that neurocognitive function improved less in people taking EFV.30 
EFV was found to cause major CNS congenital abnormalities in a number of 
nonhuman primates.3 However, new meta-analyses of the use of EFV during pregnancy 
are encouraging,31 although the data do not rule out a possible two to three time increase 
in the rates of neural tube defects associated with  EFV use during the first trimester of 
pregnancy. A retrospective analysis demonstrated that first-trimester introduction of 
pregnant women to EFV was associated with a ratio of CNS birth defects of 3.2 (95% CI; 
1.1–91; P = 0.03).32 However the generally benefits outweigh the threat and it is 
recommend that the regimen be continual in the occasion that conception happens while 
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on the medicine.33 With first-trimester exposure, a 2.3% incidence of overall birth defects 
was seen among pregnancies prospectively reported to the Antiretroviral Pregnancy 
Registry through July 2014, a amount not drastically different from that observed among 
U.S. births in the general people.35 The risk of neural tube defect is restricted in the first 5 
to 6 weeks of pregnancy, usually before pregnancy is acknowledged; there is still a 
discussion on the use of EFV in females of childbearing potential. If these data are 
confirmed, the risk-benefit profile of EFV must be reevaluated not only for the pregnant 
but also the nonpregnant population.19 
 
Protease Inhibitors 
Based on efficacy studies in adults and experience with use in pregnancy a low-
dose RTV-boosted lopinavir and a low based RTV-boosted ATV are the chosen PI drugs 
for ARV-naïve pregnant women. ATV/r is as efficient as EFV, but with smaller amount 
of CNS side effects, less rash, and a more favorable lipid profile.23 ATV has been 
associated with nephrolithiasis, nephrotoxicity, and cholelithiasis. ATV can cause 
reversible indirect hyperbilirubinemia, which may result in visible jaundice or sclera 
icterus in a small percentage of patients. Although theoretically ATV may increase the 
risk of hyperbilirubinemia in neonates, pathologic elevations have not been observed in 
studies. ATV should be co-administrated according to dosing procedure if acid-reducing 
agents are used because most favorable absorption of ATV rely on the company of food 
and low gastric pH. In an analysis from Pediatric HIV/AIDS Cohort Study (PHACS) 
ATV exposure compared to other drugs exposure in utero led to an association of late 
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language emergence at 12 months, but at 24 months that was no longer noteworthy.19, 36 
Low-dose RTV-boosted lopinavir requires twice-daily administration and a low based 
RTV-boosted ATV requires once-daily administration.15 
 
Integrase Strand Transfer Inhibitors - Alternative Treatment Option for Pregnant 
Women 
In recent years, INSTIs have largely dominated treatment developments in HIV 
infection in both treatment-naïve and experienced patients. Raltegravir (RAL) led the 
way in 2007 when it was approved with its relatively few adverse effects and minimal 
drug interactions. In 2012 elvitegravirco formulated with TDF, FTC, and cobicistat was 
approved and in 2013 dolutegravir(DTG) was approved.37 
 
Raltegravir 
RAL is an INSTI ARV agent and a preferred treatment for initial therapy in 
nonpregnant HIV-infected adults.3 RAL is the only INSTI with data during pregnancy 
which, although limited, allows it to be recommended as an alternative regimen in 
instances where drug interactions with PI treatments are a worry or when there is 
resistance or intolerance to more frequently used drugs.15 The majority reports pertaining 
to RALuse is in late pregnancy because of its quick viral load diminution seen in clinical 
trial data from non-pregnant adults compared to EFV.38-41 
RAL is primarily metabolized by hepatic glucuronidation by uridine diphosphate 
glycosyltransferase (UGT) 1A1 followed by biliary and renal excretion of the 
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glucuronide conjugate.42 Both bilirubin and RAL are metabolized by UGT 1A1, and they 
contend for albumin-binding sites.43 Bilirubin metabolism is slow instantly after birth and 
increases noticeably over the first few weeks of existence.44 RAL levels have been made 
known to increase moderately when given to individuals getting a recognized inhibitor of 
UGT1A1 activity, such as ATV.45 RAL pharmacokinetics are modestly affected by 
concomitant administration of EFV, an inducer of cytochrome inhibitor P450 enzymes, 
and RTV, a potent inhibitor of cytochrome P450 3A enzymes.46 A case report of 
noticeable rise of liver transaminases after beginning RAL in late pregnancy, which 
resolute quickly after stopping the drug, suggests that examining transaminases may be 
designated with use of this approach.47 
Previous but limited studies found RAL concentrations of cord to maternal ratios 
of 1.0-3.48, showing high placenta transfer and promise as a therapeutic agent in the 
pregnant population.41, 48, 49 Jeantils et al.49 showed that RAL was well tolerated and 81% 
of the twenty eight women on the drug had untraceable HIV RNA at delivery. Until 
2014, there were no systematic pharmacokinetic data on RAL in pregnant women. In 
2014, a published study presented data from a large series of pregnant women (total of 42 
enrolled) describing the pharmacokinetics of RAL in the 2nd and 3rd trimester of 
pregnancy compared with postpartum showing that a elevated dose is not needed.50 There 
are also inadequate information describing the postnatal elimination of transplacentally 
acquired RAL in the newborn. In a case report, one preterm infant had RAL 
concentrations present 1 month post delivery, telling extended removal.51 A recent study 
described the washout pharmacokinetics of RAL gained through transfer across the 
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placenta in newborns born to mothers getting RAL for the management of HIV infection 
during pregnancy in 22 mother-infant pairs. The study established that RAL willingly 
crossed the placenta and display prolonged elimination in some infants, resulting in infant 
RAL concentrations above the inhibitory concentration (IC95) for wild-type HIV through 
the period of compilation of the last sample, in all but one of the study newborns.52 
Dolutegravir 
Clinical trials in nonpregnant population show the efficacy, safety, lack of 
significant drug interactions, limited intrapatient variability, wide drug distribution 
including regions such as CNS and genital tractjustify DTG as a first line therapy for 
treatment-naïve patients.37 Watts et al.50 and Clarke et al.52 showed that RAL is well 
tolerated in pregnant women and had high placental transfer. These studies suggest that 
the newer INSTI like DTG has a high potential as a first line therapy for pregnant 
women. However, there are currently no clinical data available on use of DTG in 
pregnancy, and until clinical pharmacology studies are conducted in pregnant women 
informing the safe and effective use, DTG cannot be recommended for HIV-infected 
women during pregnancy.53 
DTG has activity against wild-type HIV-1, with a protein-adjusted 90% IC90 of 
0.064 µg/mL.54, 55 Against clinical isolates of HIV-2, DTG has an IC50 of 0.18nM.55 DTG 
binds to divalent cations in HIV integrase within the host nucleus thus inhibiting the 
strand transfer reaction of HIV integrase.54, 56 DTG is rapidly absorbed from the 
gastrointestinal tract (median time to maximum concentration is 2.1 hours) after oral 
administration of 50mg under fasting conditions. The presence of food increases the 
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extent and slows the rate of DTG absorption, displaying solubility-limited absorption.57 
Food should be employed when administrating DTG in patients with INSTI class 
resistance but it is not required for INSTI-naïve patients.55, 58 Distribution into the male 
and female genital tract is evident; semen, rectal, and cervicovaginal tissue 
concentrations are 7%, 17%, and 7% to 10% of steady-state serum concentrations. CSF 
concentrations (median: 18ng/mL) are similar to unbound serum concentrations (16.8 
ng/mL).59-61 
DTG is hepatically metabolized by UGT1A1 and is a minor substrate in vitro for 
UGT1A3, UGT1A9, and cytochrome P450 3A4.55 ,62 Metabolites have been detected but 
they are not considered to contribute to efficacy or adverse event outcomes and they 
account for less than 5% of circulating DTG.63 DTG pharmacokinetics are nonlinear, but 
dose-proportional increases in serum concentration are observed between 25 and 50 mg 
with the tablet formulation.55 DTG has a elimination half-life of 12 hours in HIV-infected 
subjects.64 In patients who are poor metabolizers through UGT1A1, such as adults with 
Gilbert’s syndrome, DTG clearance is reduced by 32%.65 DTG has limited interpatient 
variability with coefficients of variation below 30% for Cmax, Cmin, and area under the 
concentration-time curve (AUC).64 No difference in pharmacokinetics according to age, 
race, or sex has been observed.55 Although individuals with moderate hepatic disease 
have a 1.5 to 2-fold increase in unbound DTG concentration, they do not require a change 
in dose.55 DTG pharmacokinetics in patients with severe hepatic impairment have not 
been studied.66 
 At physiologic concentrations, DTG does not exhibit induction or inhibition of 
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UGT1A1 or CYP450 enzymes.62 There is a 10% to 14% decrease in creatine clearance 
because DTG inhibits the organic cation transporter 2 (OCT2) (IC50 = 1.93µM) and 
multidrug and toxin extrusion protein (MATE-1) (IC50 = 6.34µM).58, 67 Drugs that are 
substrates for these transporters may result in elevated plasma concentrations and 
warrants closer monitoring. Coadministration of certain drugs like dofetilide is not 
suggested because dofetilide renal tubular secretion may be altered (Table 6).58 Although 
inhibition of the renal uptake transporters, organic anion transporters 1 and 3 (OAT1, 
OAT3), is observed in vitro, there is no effect on the pharmacokinetics of the OAT 
substrates TDF and para-aminohyppurate which may suggest that in vivo inhibition is not 
clinically significant.55, 58, 68 
Table 6: Clinically Relevant Drug Interactions with the Use of EFV. Listed are some 
of the common drugs and their effects with DTG and the actions necessary to ensure 
safety or virological control. 
 
Abbreviations: DTG, DTG; BID, twice daily. 
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EFV also reduces the DTG AUC and Cmin by 57% and 75%, respectively. When 
coadministered with EFV, in the absence of PI coadministration and with no preexisting 
INSTI resistance, the dosage of DTG should be augmented to 50 mg twice daily.69 DTG 
does not interact with the HIV PIs ATV, ATV/RTV, darunavir/RTV, nelfinavir, and 
lopinavir/RTV can be coadministered without dosage adjustment.58, 68, 70DTG can be 
administered with NRTIs at standard dosage.58, 68 
Clinical trials suggest that DTG may have a higher genetic barrier to resistance 
than RAL or EVG because no treatment-surfacing resistance has been seen in treatment-
naïve patients who were treated with DTG.71 In the absence of secondary mutations, 
DTG demonstrates activity against RAL- and EVG-resistant strains of HIV-1 with 
common resistance-associated mutations (RAMs) including N155H, Q148HKR, and 
Y143CHR.72,74 In clinical studies involving ARV-naïve patients, no resistance to DTG 
has been reported.74-77 
In ARV-experienced but INSTI-naïve patients there was less than 1% who 
developed treatment-emergent RAMs to DTG; however, 45% of patients with baseline 
INSTI resistance demonstrated treatment-emergent RAMs while receiving DTG.58, 78, 79 
Results from national genotypic resistance test surveillance data suggest that 12% of 
patients with EVG- or RAL-resistant virus also have high-level DTG resistance, 
representing 2% of all patients undergoing genotypic testing between 2009-2012.80 	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Designing Drug Trials 
Recent studies have found that at least 98% of medications have no or deficient 
safety and or pharmacokinetic information to direct dosing during pregnancy and 
lactation.81, 82 There are multiple factors for this lack of guidance; the utmost concern by 
researchers and pharmaceutical corporations is the safety of experimental drugs in 
pregnant women. The possibility of disrupting organogenesis has limited studies and 
institutional internal review boards are reserved to endorse medicine trials in pregnancy 
for comparable grounds. Supplementary causes include lack of monetary reasons and the 
nonexistence of a authorization for approval.53 With a dearth of evidence, dosing 
commendations for pregnant females are usually extrapolated from data in nonpregnant 
individuals, and the majority of drugs approved in pregnancy are used “off-label”.83 
Most available data are a result of “opportunistic studies” carried out when 
pregnant females are already receiving an agent. Although invaluable, these studies are 
incomplete. Ideally, each drug’s pharmacokinetic/pharmacodynamic effects should be 
studied in each trimester of pregnancy and during the postpartum time in order to have a 
detailed knowledge and when it would be appropriate. This would provide detailed 
knowledge to adjust for dosing in pregnancy to lessen toxicity while guaranteeing 
efficiency.53 
A panel of experts convened by the Division of Microbiology and Infectious 
Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes 
of Health recommends that pharmacokinetic studies in pregnancy be conducted for new 
medications with projected or definite use in pregnancy. Studies can be started in 
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pregnant women if preclinical studies, including research in pregnant animals, and 
clinical studies, including in nonpregnant women, have been conducted and offer 
information for evaluating likely maternal and fetal hazard, there is no greater than 
smallest risk to the fetus, and the rationale of the study is the expansion of important 
biomedical understanding that cannot be gained by any different way. Clinical research 
ought to investigate the potential of DTG as a recommended ARV in the pregnant 
population.53 
The main objective of pharmacology studies in pregnant women is to conclude if 
pharmacokinetic and/or pharmacodynamic are changed amply in pregnancy to necessitate 
an alteration in dosing. If dosing is for only a short episode of time, then it may be logical 
to contrast different women during different trimesters of pregnancy and in the 
postpartum period, due to interindividual variability, a larger sample size will be needed. 
If dosing is persistent, then each subject can be assessed both during and after pregnancy, 
serving as her own control.53 
 A study protocol investigating placental drug transfer should include a 
compilation of samples for assay of drug levels in maternal blood at delivery and cord 
blood, if the experimental drug is there in the mother at the time of delivery. To 
investigate the pattern of placental drug transfer over the dosing interval, an analysis of 
maternal delivery and cord blood drug levels should include the period from maternal 
dosing. After delivery, there is a rapid alteration in physiology, followed by a continuing 
return to prepregnancy physiology over the next few weeks and months postpartum. To 
allow a return to the prepartum state, the timing of postpartum evaluations should take 
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these changes into explanation and be performed adequately extensive enough after 
delivery.53 
 Intensive sampling studies require multiple samples per participant, in order to 
perform traditional pharmacokinetic analysis to estimate each participant’s 
pharmacokinetic parameters using only information from that person. Traditional 
pharmacokinetic parameters assessed include AUC, clearance (Cl), elimination rate 
constant (k), drug half-life (T1/2), volume of distribution (Vd), absorption rate constant, 
peak concentration (Cmax), time of Cmax (Tmax), and bioavailability. When the predictable 
effects of pregnancy on drug disposition are difficult to foresee, rigorous sampling and 
conventional pharmacokinetic analysis may be particularly practical, so collecting 
multiple samples is necessary to have sufficient data to characterize absorption, 
distribution, and clearance with confidence.53 
 Population pharmacokinetic examination involves compilation of smaller number 
of samples from each individual in a bigger collection of participants. This technique can 
utilize all accessible information and incorporate information from several sources 
providing estimates for typical principles for pharmacokinetic constraints for the 
population and as well describes changeability in pharmacokinetic parameters across the 
population. Once population pharmacokinetic prototypes are developed, modeling and 
simulation can be used to direct generation of a dosing algorithm, with specific 
suggestions for dose adjustments by state of pregnancy or other factors, such as obesity, 
race, and disease state.53 
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PUBLISHED STUDIES (lit-based) 
 
EFV needs to be reconsidered as a first-line ART due to animal teratogenic 
possiblity and frequent neuropsychiatric unfavorable occurrences associated with its use, 
including increased threat of suicidality when compared with different ARV drugs. Most 
notably, EFV has demonstrated overall inferior potency to various comparator ARVs, 
which consist of RPV, RAL and DTG, in ARV-naïve individuals. Additional, 
epidemiological information display that the pervasiveness of NNRTI resistance has 
reached five to eight percent in diverse parts of the globe, and minority transmitted 
NNRTI resistance associated mutations may have a negative effect on the conclusion of 
first-line EFV-based ART.19 
The STaR study was a multicentre, international, randomized, open-label phase 
3b 96 week study that evaluated two single tablet regimens, TDF/FTC/EFV and 
TDF/FTC/RPV, as a first line ART in 786 HIV-1 ARV-naïve patients. The study 
indicated the dominance of RPV-based treatment relative to EFV-based treatment. The 
percentages of patients achieving virological suppression were eighty percent and eighty 
percent at weeks 48 and seventy three percent and seventy nine percent at week 96 for 
TDF/FTC/EFV and TDF/FTC/RPV, respectively.72,73 The 95% CIs for the differences 
were 0.6%–11.2% at week 48 (P=0.03) and 0.7%–12.6% at week 96 (P=0.03).84, 85 
There was a significant difference in virological control at week 96 favoring the 
RPV-based regimen in a group of patients with baseline HIV-1 RNA ≤ 100,000 
copies/mL, seventy nine percent versus seventy one percent, 95% CI for difference: 
0.2%–15.1%; P=0.048.32 In the other group, patients with baseline HIV-1 ≥ 100,000 
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copies/mL, the RPV-based regimen was non-inferior EFV-based regimen, 76% versus 
75%, 95% CI for difference: 8.7%–11.6%; P=0.78.84 There were significant fewer 
nervous system and psychiatric adverse events using RPV-based regimen compared with 
the EFV-based regimen (P<0.001) and significant fewer discontinuation for unfavorable 
effects, three percent versus eleven percent, respectively (Table 7).19 
The STARTMRK trial was similar to the STaR study in the aspect that they were 
both randomized and used TDF plus FTC as an NNRTI backbone in treatment-naïve 
patients. However STARTMRK trail was a double-blind study comparing RAL and EFV 
and it was not a single-tablet regimen. Patients were on active EFV as part of their night-
time treatment and a placebo in the morning. RAL was dosed twice daily.86 Despite EFV 
possessing a far longer plasma half-life than RAL, the data suggested RAL to be superior 
to EFV at week 192 of treatment. Therefore any amount of non-adherence in the 
STARTMRK trial should have favored the EFV treatment and the superiority of RAL 
over EFV could be seen as more dramatic than the results of the intent-to-treat analysis 
would seem to suggest. At week 240 patients with HIV RNA<50 copies/mL were 
seventy one percent and sixty one percent for RAL and EFV, respectively (95% CI: 1.7–
17.3%).71 In regard to lipid profile, RAL is more beneficial compared to EFV.86 Similar 
to the STaR there was notably fewer ARV-related clinical adverse events occurred in 
patients taking RAL compared to EFV (P<0.0001).87-90 
The SINGLE study was a randomized, double-blind phase 3, 96 week study that 
evaluated two once-daily regimens, a TDF/FTC/EFV to a ABC/3TC/DTG single-tablet 
regimen in 833 HIV-1 ART-naïve adults. At weeks 48 and 96, there was a significant 
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higher number of patients having HIV-1 RNA <50 copies/mL in the ABC/3TC/DTG 
patients than in the TDF/FTC/EFV company (88% versus 81%; P=0.003). Rates of 
discontinuation due to adverse effects were also higher in the TDF/FTC/EFV company 
than the ABC/ 3TC/DTG group (10% versus 2%).75 Table 7 compares the unfavorable 
events by week 48 in selected EFV-based randomized clinical trials performed in ARV-
naïve patients to comparator drugs.  The ECHO and THRIVE studies both used RPV as 
the comparator drug. EFV has demonstrated overall inferior efficacy and higher rates of 
discontinuation compared to rilpivirine, RAL, and DTG.19 
Table 7: Percentage of Discontinuations due to Adverse Effects. Percentage of 
unfavorable occasions by week forty-eight in selected EFV-regimens clinical trials 
performed in ARV-naïve individuals 
 
 
In 2001–2004, randomized first-line clinical studies in the USA compared EFV-
containing regimen with a non-EFV-containing regimens. They found the prevalence of 
standard NNRTI resistance was five percent and the threat of virological failure for 
individuals with standard NNRTI was more than for patients without such resistance 
(ratio = 2.7, 95% CI: 1.15-4.49; P = 0.018).91 The likelihood of failure to suppress viral 
replication involving first-line EFV- or NVP-based therapy is significantly associated 
with detection of low-level NNRTI resistance.92 The threat of virological failure was 
twice as high in individuals with transmitted NNRTI drug resistance, in the EuroCoord-
CHAIN joint project.93 Similarly a meta-analysis of 985 participants from ten studies 
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showed that there was 2-times to 3-times associated greater risk of virological failure 
when drug-naïve patients start a NNRTI-based treatment when they showed a minority 
HIV-NNRTI drug resistance mutation.94 A case-control study of 260 patients in Europe 
demonstrated patients on first line NNRTI-based treatments with minority NNRTI 
resistance mutations at standard were related with an adjusted 2.4 times increased risk of 
virological rebound of HIV-1 RNA to >200 copies/mL in individuals (95% CI: 1.12-
5.18; P = 0.024).95 
The pervasiveness of NNRTI resistance mutations in ARV-naïve individuals and 
low genetic barrier of NNRTIs to progress to drug resistance puts EFV in a major 
disadvantage when considering the best regimen.96 Epidemiological data indicate that the 
prevalence on NNRTI resistance is either steady or dropping in various parts of the globe, 
5%-8%, which can have a serious negative result on the outcome of treatment when using 
EFV.97,98 Furthermore, these result do not consider the presence of minority NNRTI 
resistance mutations.95, 99 In patients with advanced HIV-infection, failing treatment can 
lead to suboptimal immunological recovery which can lead to increased morbidity and 
mortality associated with insufficient virological restraint. Failure to treat individuals 
with first-line NNRTI-based regimens can lead to further accumulation of NNRTI and 
NRTI resistance mutations, which can lead to cross-resistance to second-generation 
NNRTIs and diminish the efficiency of nucleoside backbone and nonnucleoside ARVs of 
subsequent treatment, respectively.19 In high-income countries, HIV genotypic resistance 
testing is recommended before initiating therapy with NNRTI due to an increased 
pervasiveness of transmitted ARV resistance to NNRTIs. Unfortunately this practice is 
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not generally possible in low-income or developing regions, where resources for 
resistance testing are limited.2 
Due to efficacy, toxicity, and the pervasiveness of NNRTI resistance, which leads 
to the probability of virological failure when using EFV, EFV should be reconsidered a 
preferred therapeutic option in both nonpregnant and pregnant populations. Alternatives 
need to be considered especially when advances in treatments resulted in safer and more 
effective ARVs. A decision to no longer recommend EFV in limited settings will only be 
reasonable if safer and more effective ARVs are accessible for use as third agents in 
cART, and this suggestions should be reflected in the treatment guidelines of the WHO, 
especially since following up on issues like drug toxicities and transmitted resistance is 
often not pragmatic in these regions.19 
The study conducted by Watts et al compares the pharmacokinetics of RAL in the 
second and third trimesters of pregnancy to postpartum. Only HIV-infected pregnant 
women who were receiving RAL, 400 mg twice daily, before the beginning of the 35th 
week of pregnancy were considered. Women enrolling in the second trimester had 
pharmacokinetics sampling determined within 2 weeks of receiving the samples between 
20 and 26 weeks of gestation and again between 30 and 36 weeks of gestation. Women 
enrolled in the third trimester of pregnancy had RAL pharmacokinetic sampling operated 
between 30 and 36 weeks of gestation. All women had pharmacokinetic sampling again 
between six and twelve weeks of postpartum. The RAL trough (C12h) in nonpregnant 
adult populations was used to compare the observed RAL trough for each pregnant 
mother.100 Within 2 weeks of sampling during pregnancy; subject’s plasma 
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concentrations and C12h was announced to each subject’s physician. The physician then 
was granted the option of discussing the result and possible dose adjustment with a study 
team pharmacologist if the C12h was below the estimated 10th percentile in nonpregnant 
adult populations (0.035 µg/mL).100 Pharmacokinetic sampling was only performed when 
subjects were steady on their ARV treatment for at least 2 weeks. Seven plasma samples 
were performed at the second trimester, third trimester, and during postpartum 
pharmacokinetic parameters, including predose, 1, 2, 4, 6, 8, and 12 hours after dosing. 
To minimize variability of the pharmacokinetic parameters, women were required to fast 
2 hours before and after dosage. A maternal plasma sample and an umbilical cord sample 
after cord clamping were collected at delivery.50 
 During each study visit, HIV-related laboratory testing was performed if not 
available as part of routine clinical care. HIV RNA assays had lower limits of detection 
ranging from 20 to 400 copies per milliliter. RAL concentrations were measured using a 
validated liquid chromatography tandem mass spectrometry method, with a lower limit of 
quantitation of 0.010 µg/mL. Laboratory assays, history and physical examination was 
assessed on each pharmacokinetic sampling day, at delivery, and at 24-week postpartum 
to monitor maternal clinical and laboratory toxicity. HIV infection status, gestational age 
at birth, and infant birth weight were recorded. To classify unfavorable events for study 
individuals The Division of AIDS/ National Institute of Allergy and Infectious Diseases 
Toxicity Table for Grading Severity of Adult Adverse Experience was used 
(http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx).50 
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Forty-two women were enrolled, with 16 completing second trimester sampling, 
41 completing third trimester sampling, and 38 completing sampling postpartum. Half of 
the participants were on regimens of 2 or more NRTI only with RAL, whereas the other 
half were on treatments that involved ARVs from at least 3 classes. Out of the 17 women 
on RAL with only nucleosides, 16 were ARV-naive patients compared with 9 of the 23 
on treatments with drugs from 3 or more categories. During the third trimester and at 
delivery, at least ninety of women had HIV RNA levels below 400 copies per millimeter. 
Women on their first ARV regimen may have been approved for RAL instead of current 
first-line therapy due to its tolerability in nonpregnant adults or because of the need for 
concomitant therapy that would interact with PIs. Even the women with multiple 
previous treatments and multiple categories of drugs including at least 3 classes of agents, 
92% of all women had below detectable HIV RNA levels at delivery and RAL served as 
an additional new mechanism of activity. All infants were at least 36 weeks of gestation 
at delivery and none of the infants were infected.50 
No major anomalies were judged to be related to RAL use based on timing of 
exposure and family history, although 7 infants had congenital anomalies. Four women 
were noted with grade 3 or 4 toxicities, including, shortness of breath and hypertension in 
1, fever in 1, face/scalp rash and gum pain in 1, drainage from the abdominal cesarean 
delivery incision, elevated amylase, vaginal bleeding and uterine pain in another. 
However none of these were attributed to be treatment related. RAL was well tolerated in 
pregnancy. Although results are too limited to rule out uncommon adverse events, this is 
the largest series to date of RAL use in pregnancy. Possibly treatment-related toxicities 
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included intermittent vomiting in 1 subject, transient liver transaminase elevations in 
another subject, graded as moderate toxicity (grade 2).50 
RAL pharmacokinetic parameters at each sampling interval are presented in Table 
8. No notably difference between pregnancy and postpartum sampling in half-life, oral 
clearance, and apparent volume of concentration was detected. No notable differences 
were found between the second and third trimester trimesters in a comparison of subjects 
with sampling at both times. Thirty-eight percent of the women in the second trimester, 
32% in the third trimester, and 13% postpartum had delays in absorption of RAL, or a 
one-hour postdose concentration lower than the predose concentration. In the second 
trimester Cmax ranged from 0.365 to 5.960 µg/mL, in the third trimester it ranged from 
0.315 to 7.820 µg/mL and from 0.312 to 12.600 µg/mL postpartum. The target RAL C12h 
was 0.035 µg/mL and 69% subjects in the second trimester exceeded that value, 80% in 
the third trimester, and 79% postpartum. Trough concentration in the second trimester 
compared to trough postpartum was significantly lower. Pharmacokinetic parameters 
were quite irregular, and the volatility increased from second to third trimester and into 
the postpartum period. Cmin during the second trimester ranged from below the 
quantifiable limit to 0.162 µg/mL, BQL to 0.607 µg/mL in the third trimester, and BQL 
to 0.917 µg/mL postpartum. The peak concentration in the third trimester compared with 
the peak concentration during postpartum was significantly lower. Median AUC0-12 
showed wide variability and was notably lower in the second and third trimester 
compared with postpartum.50 
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Table 8: RAL Pharmacokinetic Parameters at Each Sampling Interval. RAL Median 
(Range) Noncompartmental Pharmacokinetic Parameters for Comparison to Postpartum
 
 
Two women were taking concomitant RTV-boosted ATV, which may increase 
RAL exposure. One subject taking ATV/RTV had below RAL target trough 
concentrations during the third trimester but above the threshold in the second trimester 
and postpartum. The other patient taking ATV/RTV had trough concentrations above the 
threshold in the third trimester and postpartum. Although ATV is a known inhibitor of 
UGT1A1 and RAL is primarily metabolized by UGT1A1, the two women showed that 
RAL exposures were not out of the range seen in the other individuals.85 When the 2 
largest ethnic groups represented in our sample, no notable difference in RAL AUC was 
observed.50 
RAL exposure was reduced during pregnancy: approximately fifty percent 
decreased median AUC during the second and third trimesters than in the same female 
postpartum, the C12hof RAL was below the target level in more than ten percent of 
females at each sampling time, about a third of women during pregnancy indicated an 
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absorption lag compared with ten percent of women postpartum. The C12h was 
fluctuating; ranging from 0.0114 to 1.340 µg/mL.50 However this is persistent with RAL 
pharmacokinetic data in nonpregnant adults studied by Wohl et al.101, where median C12h 
was 0.091 µg/mL with a scope of 0.010–1.386 µg/mL. By the 4th week of treatment, 95% 
of subjects had an HIV RNA level lower than 200 copies per milliliter, despite the wide 
fluctuation.101 The analysis of pharmacokinetic and viral response data from the 
BENCHMRK 1 and 2 trials showed wide fluctuation in RAL plasma level and 
insufficient relationship between RAL levels and virologic response in nonpregnant 
adults.102 
After evaluating their data, Watts et al. recommended no adjustment for 
pregnancy dosing from the standard in nonpregnant patients even when median RAL 
AUC was lowered by approximately 50% during pregnancy because RAL’s ability to 
cross the placenta, high rates of viral control at delivery, and the large fluctuation in RAL 
plasma levels seen in nonpregnant patients, and the insufficient relationship between 
RAL levels and virologic results.50 
The median maternal RAL concentration at delivery was 0.140 µg/mL, and the 
median cord blood concentration was 0.154 µg/mL. The median cord/maternal ratio was 
1.5, the high placenta transfer of suggest that RAL can be used to bring pre-exposure 
prophylaxis against HIV exposure in the fetus.52 Figure 2 shows maternal delivery and 
cord blood RAL concentrations and the ratio are plotted as a function of the time period 
between maternal dosing and delivery.50 
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Figure 2: Maternal Delivery and Cord Blood RAL Concentrations and their Ratio 
as a function of Time. Median RAL concentration-time curves during the 2nd trimester, 
3rd trimester, and postpartum. The dashed lines display the concentration-time profile in 
nonpregnant adults. 
	  44 
Clarke et al.52 focused on washout pharmacokinetics and safety of in utero and 
intrapartum exposure to RAL acquired through the placenta in full term neonates born to 
HIV-infected pregnant females receiving RAL-regimen ART. HIV-infected mothers and 
their newborns were enlisted before delivery if the mother was given the standard dose of 
RAL, for at least 2 weeks before delivery cART and had a single gestation. Maternal 
plasma and cord blood concentration for RAL assay were obtained at the time of 
delivery. To determine UGT1A1 genetic polymorphisms, dried blood spots were 
obtained from neonates. Blood was drawn from study neonates for liver transaminases, 
total and direct bilirubin, and creatine after birth and for complete blood counts. 
Newborns were observed until 20 weeks after birth for signs of RAL toxicity. The 
infant’s clinical care was evaluated. 
Twenty-two mother-infant pairs were enrolled, maternal plasma and cord blood 
samples were available from nineteen mothers. Figure 3A shows the relationship between 
the time interval from maternal dosing to delivery and maternal delivery level and cord 
blood level. Figure 3B shows the relationship between the time intervals from maternal 
dosing to cord blood to maternal delivery level ratio. The median cord blood RAL level 
was 957 (range, 24-3947) ng/mL and the median maternal RAL level at delivery was 540 
(range, 12-5809) ng/mL at a median 4.6 (1.1-21.0) hours. The median cord blood RAL to 
median maternal RAL concentration ratio is 1.48, ranging from 0.32 to 4.33. RAL freely 
crossed the placenta so that by three hours after maternal dosing, the umbilical cord RAL 
level exceeded or equaled the maternal plasma level at the time of delivery.52 Similar to 
Watts et al.50 results, high placenta transfer suggest RAL can be used as a prophylaxis 
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against HIV risk in the fetus before and even after delivery. 
Figure 3: The Relationship between Time Interval from Maternal Dosing to RAL 
Concentration and Cord/Maternal Plasma Ratio. A RAL levels in cord blood 
(crosses) and maternal plasma at delivery (diamonds). B, Ratio of cord blood to maternal 
plasma concentration plotted against time between maternal dosing and delivery. 
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No stillbirth or infant death was observed. Five newborns had grade three or four 
laboratory occurrence, two had grade three or four signs and symptoms which included 
neonatal respiratory discomfort and fever, and one newborn had grade three or four 
diagnosis, endocrine and metabolic disorder. There was one newborn with below birth 
weight. However, none of these adverse event s reported in infants were suggested to be 
associated to maternal RAL use.52 
Figure 4 presents individual infant RAL concentration-time plots. Median 
newborn levels and the time of collection after birth were 671 ng/mL at 1.9 hours, 507 
ng/mL at 20.5 hours, 481 ng/mL at 20.5 hours, and 291 ng/mL at 33.8 hours. RAL level 
rose over the initial twelve to twenty-four hours after birth before dropping in 47% of the 
infants. In another infant, elimination t1/2 could not be calculated because in the last 3 
samples because there was no decline in the RAL concentration. Several of the infants 
had elimination t1/2 in the scope akin to those reported in nonpregnant adults, 7–12 hours, 
many displayed slower elimination, with the longest t1/2 being 184 hours.103 For 17 
infants for whom an elimination t1/2 could be calculated, the minimum elimination t1/2 
was 9.3 hours, a maximum of 184 hours, median of 26.6 hours, and an interquartile range 
of 22.0–69.2 hours.52 
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Figure 4: Individual plots of RAL concentration versus time after delivery. Light 
dashed line display the RAL IC95 for wild-type virus of 14 ng/mL. Heavy dashed lines 
display median concentration at each sampling time period. 
 
RAL elimination was vastly fluctuating and extended in some newborns. For 47% 
of the infants, RAL levels rose over the first twelve to twenty-four hours after birth 
before dropping.52 This is likely explained by enterohepatic recirculation, where beta-
glucuronidase present in the brush border of the fetal and neonatal gut breaks down 
luminal substrate-glucuronide complexes and allows intestinal reabsorption of the now 
unconjugated substrates.104 Gut motility and RAL metabolism are slow immediately after 
birth, which results in a primary rise in RAL blood levels like those seen in 
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approximately half the study newborns because the RAL glucuronide present in 
meconium undergoes deconjugation followed by reabsorption of the unconjugated 
RAL.52 
Of the twenty-two newborns enlisted, the UGT1A1 genotyping was obtained for 
17 infants (Table 8). Of the 17 infants with UGT1A1 genotyping, 16 infants had 
pharmacokinetic evaluations successfully performed. Eight infants were homozygotes 
(TA)6/(TA)6, one was (TA)7/(TA)7 homozygote, seven were (TA)6/(TA)7 heterozygotes, 
and one was (TA)5/(TA)6 heterozygote. Only 1 newborn received phototherapy to treat 
hyperbilirubinemia. This infant was (TA)6/(TA)7 heterozygous and had a RAL t1/2 of 75.4 
hours.52 Prolonged RAL elimination in neonates is most likely due to low neonatal 
UGT1A1 enzyme activity and enterohepatic recirculation rather than infant genotype. 
When the (TA)6/(TA)6 newborns were analyzed with the newborns with the other 3 
UGT1A1 genotypes, there was no differences in median RAL levels in elimination t1/2 or 
at any time period.103 As a consequence of the sufficient placental transport and 
prolonged newborn elimination of RAL, newborn RAL levels remained above the IC95, 
14ng/mL, for wild-type HIV through thirty to thirty six hours after delivery, the time of 
collection of the last sample, in all but one of the newborns.52 
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Table 9: RAL Elimination t1/2, UGT1A1 Genotype, and Need for Phototherapy 
UGT1A1 was obtained for 17 infants and pharmacokinetic evaluations were performed 
on 16 newborns. 
 
 As well as to sharing major elimination pathways, RAL and bilirubin also contend 
for plasma albumin binding sites. If the unconjugated bilirubin concentration elevates 
above the plasma albumin-binding capacity, then circulating unbound bilirubin is 
accessible to cross the blood-brain barrier and cause bilirubin linked mortality CNS 
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toxicity such as kernicterus.105 Yet, the binding affinity of albumin to RAL is much lower 
than that of bilirubin. In an vitro study in neonatal serum, RAL displayed notable 
displacement of bilirubin from albumin only at concentrations 50–100 fold greater than 
normal therapeutic levels.43 Since high RAL concentration in the plasma may elevate the 
threat of bilirubin neurotoxicity, excessive RAL levels must be avoided in the neonate by 
adjusting neonatal RAL dosing regimen over the first weeks of life. There is a heightened 
risk of toxicity when administrating RAL because RAL and bilirubin elimination is 
extended and plasma albumin is more permeable in preterm infants. Conversely 
subtherapeutic concentrations could result in insufficient viral control and develop to 
RAL resistance.52 
Although there is no datum on DTG use during pregnancy, the promise of DTG in 
both ARV-naïve and experienced adults, and the experience with use of RAL during 
pregnancy, suggest clinical studies should be conducted to see if DTG could serve as an 
alternative first-line regimen. In two clinical trials, the efficacy of DTG in ARV-naïve 
nonpregnant adults has been analyzed. DTG was not inferior to RAL, while DTG was 
superior to EFV.37 
Two randomized double-blind, multicenter Phase III clinical trials examine the 
utility of DTG in HIV-infected, treatment-naïve nonpregnant individuals to establish 
safety, efficacy, and tolerability. Noteworthy findings included demonstrated efficacy, 
overall safety, minimal adverse effects, rapid virologic suppression, minimal virologic 
breakthrough, and lack of INSTI or other major mutations.37 
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SPRING-2 contrasted DTG 50 mg daily to RAL 400 mg twice daily in 
combination with an NRTI-backbone of either TDF/FTC or ABC/3TC. The study 
randomized 822 subjects who received study drugs (half DTG and the other half RAL). 
Sixty percent received TDF/FTC as the NRTI backbone. No significant differences in 
achieving the same number of patients (88% in the DTG group and 86% in the RAL 
group) with viral load <50 copies/mL at week 48 was found to be associated with NRTI-
backbone or baseline viral load, meeting the 10% noninferiority criteria. Although there 
was a favorable trend toward DTG in adults with baseline CD4 cell counts <350 and 
<200 cells/mm3, it did not reach statistical significance. Other similarities included time 
to viral suppression, safety profiles, laboratory changes, and adverse events leading to 
discontinuation. More patients in the RAL group had protocol-defined virologic failure 
(PDVF) compared to the DTG group. Of those that met PDVF, 5 patients in the RAL 
group had genotypic mutations while none were noted in the DTG group.75 A total of 681 
patients were reassessed at week 96 of treatment. Results were similar to those of 48 
weeks, similar CD4 cell count increases, rates of discontinuation and viral suppression 
(81% in the DTG group relative to 76% of those treated with RAL). Between weeks 48 
and 96, there were 2 adults in the DTG group and 1 adult in the RAL group who had 
PDVF; however, no resistance mutations were detected in either group.106 
The SINGLE study was a noninferiority, randomized, double-blind, multicenter 
trial that ran through 144 weeks comparing once daily DTG 50 mg with fixed-dose 
ABC/3TC to TDF/FTC/EFV as a fixed-dose combination tablet. If noninferiority were 
met in both per-protocol and intent-to-treat analyses, superiority would be assessed. A 
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total of 844 patients were randomized with 833 patients receiving study drug (414 in the 
DTG group and 419 in the EFV group). Eighty-eight percent of patients receiving the 
DTG regimen compared to the 81% receiving the EFV regimen reached a viral load <50 
copies/mL, at week 48; the difference between the two groups met noninferiority criteria. 
Superiority analysis demonstrated a statistically significant difference between the DTG-
treated patients and EFV-treated patients for number of patients with viral load <50 
copies/mL at week 48, in favor of DTG-based regimen (P=0.003). No difference in 
virologic response was noted in baseline viral load or other subgroups. PDVF occurred in 
4% of the patients and was similar between the treatment arms. There was a statistically 
significant difference in CD4 cell count for DTG, 267 cells/mm3 versus 208 cells/mm3 
(P<0.001), and a significant decrease in the time it takes for viral suppression in the DTG 
group, 28 days versus 84 days.76 No major NRTI or INSTI mutations were detected in the 
DTG arm; however, 1 NRTI and 4 NNTRI mutations were noted in the EFV arm. All 844 
patients from the 48-week study period continued on study and additional assessments 
were held at week 96. The rates of virologic failure between the groups were similar. 
There was no virologic resistance observed between weeks 48 and 96 in the DTG group. 
However there was resistance detected in seven patients who received the EFV-based 
regimen, one NRI and six NNRTI. There was a significant (P=0.006) number of patients 
on the DTG arm who had <50 copies/mL compared to the EFV arm (80% versus 72%). 
There was a continuous increase in CD4 cell count with DTG (325 cells/mm3 versus 281 
cells/mm3, P=0.004).107 From 96 weeks to 144 weeks were the open-label phase, DTG 
continued to demonstrate superiority and long-term viral load suppression compared to 
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EFV arm (71% versus 63%, P=0.010). Discontinuation of study drug occurred more 
frequently in the EFV arm, 14%, compared to DTG, 4%. Although genotypic resistance 
was not detected in the DTG arm, PDVF was similar between groups (9% DTG versus 
8% EFV). Seven patients in the EFV arm had detectable genotypic resistance (one NRTI, 
six NNRTI).106 
Patients receiving DTG experienced relatively few adverse effects: insomnia and 
headaches were most common, with an incidence of ≥ two percent in the clinical trials. 
Hypersensitivity reactions were reported in <1% of trial participants. DTG subjects had 
no major NRTI or INSTI mutations during trials, suggesting a higher genetic barrier to 
resistance than for RAL or EVG. No deaths related to study drug occurred in any trail, 
although there was rise in serum creatine, attributed to the inhibition of renal tubular 
creatine secretion by OCT2. DTG-based regimen showed superiority compared to EFV-
based regimen to reaching viral load <50 copies/mL at 48 and 96 weeks. DTG-based 
regimen showed noninferiority compared to RAL-based regimen. More patients in the 
RAL group had PDVF compared to the DTG group.37 
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DISCUSSION 
 
In the light of new data, we need to constantly re-examine what is to be considered to be 
an approved treatment. Although there is wide experimentation with various different 
ARV drug combination conducted in the HIV-positive nonpregnant population, there are 
limited studies investigating ARV drug combination in pregnant women to maintain 
maternal health and prevent MTCT. Information is limited and multiple factors hinder 
drugs studies in pregnant patients, including concerns for maternal and fetal safety, 
ethical considerations, the difficulty in designing appropriate trials to assess the study 
objectives, and funding limitations. 
An optimal drug regimen is one that is effective and well tolerated while requiring 
little long-term monitoring. A major advantage would be if the drug could be assimilated 
into a once-daily and one-pill regimen to increase convenience and potential for 
improved patient adherence. The current WHO6 preferred initial ARV regimen to treat 
HIV-pregnant women consists of two NRTIs in combination with either EFV or a 
boosted PI. It does not include a drug from the INSTI class, a drug that has shown to have 
advantages over other classes of ARV drugs in the nonpregnant population. There are 
either limited or no data in use of INSTI in HIV-infected pregnant patients. However, 
current data advise that EFV should be reevaluated as first-line therapy, and that drugs 
from the INSTI class should be considered as a first-line therapy as experience with 
INSTI use in pregnancy increases. 
Despite its long use, EFV is being reconsidered as WHO6 first-line ART because 
of its poorer overall efficacy compared with newer ARVs, its ranking as FDA Pregnancy 
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Category D drug, the relatively high prevalence of transmitted drug-resistance mutations, 
and adverse events including CNS and psychiatric side effects. Some of these adverse can 
lead to treatment discontinuation.  
The STARTMRK trial showed that RAL was superior to EFV, although the 
evidence that show that EFV has a greater plasma half-life than RAL, meaning any 
failure to adherence in this study ought to have favored the EFV and demonstrated 
superiority over EFV. RAL also showed a benefit in regard to lipid profile. The SINGLE 
study showed that the proportion of patients having HIV-1 RNA < 50 copies/mL on the 
DTG treatment was significantly higher than the proportion of patients on the EFV 
regimen. There were more discontinuations, nervous system and psychiatric adverse 
effects in the EFV arm compared to the comparator drug. These studies show that new 
types of drugs like INSTI are superior and better tolerated than EFV based regimen. 
Furthermore, RAL and DTG have less pill interactions than NNRTIs, PIs/r, and 
EVG/cobi/TDF/FTC.19 
Although limited data exist in the pregnant populations, RAL is advised under 
special circumstances where resistance, intolerance, or incomplete virologic response to 
more commonly used agents, NNRTI or PI was observed. In patients with previous 
regimens with suboptimal virologic control, RAL could be considered as an additional 
novel mechanism of activity.  RAL was well tolerated, readily crossed the placenta, 
displayed few drug interactions and demonstrated a rapid decrease in HIV RNA levels 
suggesting it safe and effective to use for the mother and serve as a pre-prophylaxis 
against HIV exposure in the fetus.50, 52 
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Currently there are no data describing DTG use in pregnancy, but studies in 
nonpregnant population suggest that DTG may have significant advantages over RAL, 
and clinical trials should be implemented to understand the 
pharmacokinetic/pharmacodynamic of DTG in pregnancy. In nonpregnant adults, studies 
showed that DTG was noninferior to RAL, fewer PDVF, wider drug distribution 
including the cerebrospinal fluid (CSF) and the male and female genital tract, and 
displayed no treatment-emergent resistance implying that it may have a higher genetic 
barrier to resistance compared to the other INSTI, RAL and EVG. Furthermore DTG-
based regimens are easier to adhere by because they are available in combination with 
ABC and 3TC as a once daily dosing regimen, like EVG-based regimen, but with 
relatively few drug interactions, similar to RAL-based regimen. Furthermore DTG is the 
only single tablet regimen for patient with or at risk for renal dysfunction.37 
Studies on pregnant animals, and clinical studies, including studies in 
nonpregnant women, have been conducted and provide data for assessing potential risk to 
pregnant women and fetuses; and the risk to the fetus is not greater than minimal and the 
purpose of the research is the development of important biomedical knowledge which 
cannot be obtained by any other means. Pharmacokinetic/pharmacodynamic information 
achieved during pregnancy are essential to inform acceptable dosing, because 
extrapolation of dosing from results performed in nonpregnant patients fails to take into 
consideration the impact of the multiple physiologic alterations that occur during 
pregnancy. If DTG is going to be prescribed for pregnant women, then it is suggested that 
clinical research in pregnant women be conducted.53 
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Although DTG was well-tolerated in clinical trials headaches, insomnia, and 
hypersensitivity reactions did occur in some patients. Furthermore DTG decreases tubular 
secretion of creatine, which lead to modest elevations in serum creatine in some patients 
soon after the drug, is initiated, suggesting frequent and close monitoring of the patient 
until larger experience is gained.37 To prevent ongoing enlistment of patients getting 
possibly insufficient dosing, early stopping of enlistment is to be advised using a 
statistical rationale for early stopping criterion. Notifying patient’s doctor of the patient’s 
drug plasma levels and C12h during pregnancy or therapeutic monitoring should be used 
to avoid potential inadequate DTG exposure, which may lead to inadequate virologic 
suppression. Infants born to mothers treated with an ARV drug during a clinical trial 
should be monitored after birth for signs of toxicity.53 
  
	  58 
CONCLUSION 
 
Advances in prevention of MTCT of HIV and in keeping HIV infected mothers 
alive have been very promising, leading to recommendations to provide ART for all 
pregnant women. However too many children are still being newly infected with HIV and 
efforts are needed to accelerate availability of ART to all HIV infected pregnant women 
so we can eliminate MTCT of HIV. Advances in ART treatments have now developed in 
safer and virologically superior alternatives to the current first-line regimen, 
TDF/FTC/EFV for both pregnant and nonpregnant adults. Similar to multiple other 
drugs, EFV should be reconsidered as first-line therapy, due to considerations of efficacy, 
toxicity and resistance.  
 Based on results, RAL offers one alternative to treat HIV-infected pregnant 
patients. Subjects in pharmacokinetic studies showed high percentages of viral control 
and high placental transfer with the use of RAL in HIV-infected women during 
pregnancy and postpartum s. Although median AUC was reduced during pregnancy, 
trough concentrations were frequently below objective levels both during late pregnancy 
and postpartum and the lack of a clear correlation between RAL level and virologic effect 
in nonpregnant adult simply that a larger RAL dose is not required during pregnancy. 
 There are no current studies of DTG use during pregnancy but the success of 
DTG in nonpregnant women and the advantages of using RAL during pregnancy suggest 
that DTG can be advantageous. Similar to RAL, DTG is an INSTI and has fewer drug 
interactions compared with PIs or EFV. DTG was noninferior and had fewer PDVF 
compared to RAL. DTG with ABC and 3TC, available once daily dosing has a significant 
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advantage over a RAL-based regimen that requires twice a day dosing. DTG has showed 
a wider drug distribution including the CSF and the male and female genital tract. DTG 
has showed no treatment-emergent resistance implying that DTG may have a larger 
genetic barrier to resistance compared to RAL. 
 A decision to no longer recommend EFV will only be ethical if the safer and more 
effective alternative ARVs are accessible for use as third agents in cART. We should 
continually appraise what we suggested and test current criterion, especially when 
preclinical studies and clinical studies in nonpregnant women provide data relative to 
creating clinical studies in pregnancy to further develop the understanding in this area 
and improve the healthcare and results for pregnant women and their newborns. 
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Office Assistant    September 2009 – August 2011 
• Oversaw client relations via telecommunications 
• Managed check processing, receipts, and records for rental properties 
• Transported documents to various on-campus departments  
 
VOLUNTEER EXPERIENCES 
Volunteer Services, Brigham and Women’s Hospital – Boston, MA 
Outpatient Infusion Volunteer   August 2011 – May 2014 
• Orchestrated incoming patients to assigned seating and providing 
refreshments, blankets, pillow, or company. 
• Transported laboratory specimens and drugs to pharmacy, laboratory, and 
outpatient infusion services. 
• Stock all cabinets with proper medical equipment and sterilizing equipment 
after use. 
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Pre-Practicum Experience, Boston Community Leadership Academy – 
Brighton, MA 
Teaching Assistant     January 2012 – May 2012 
• Prepare lesson plans for high school chemistry and biology classes 
• Assisting students by answering questions and clarifying concepts 
 
Community Service Center, Wizards, Boston University – Boston, MA 
Experiment Coordinator    January 2011 – Sept 2012 
• Conducted planned science experiments with elementary and middle school 
students 
• Managed experiment equipment and perform inventory 
• Prepared lesson plans for hands-on science experiments with elementary and 
middle school students 
• Communicated weekly progressions of the program to internal and external 
staff 
 
